Copyright Reports & Markets. All rights reserved.

Global In-Situ Hybridization Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 In-Situ Hybridization Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global In-Situ Hybridization Market Size Growth Rate by Product
      • 1.4.2 Radioactive isotopes
      • 1.4.3 Non-radioactive labels
    • 1.5 Market by End User
      • 1.5.1 Global In-Situ Hybridization Market Size Growth Rate by End User
      • 1.5.2 Cancer Diagnosis
      • 1.5.3 Immunology
      • 1.5.4 Neuroscience
      • 1.5.5 Cytology
      • 1.5.6 Infectious Diseases
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global In-Situ Hybridization Market Size
      • 2.1.1 Global In-Situ Hybridization Revenue 2014-2025
      • 2.1.2 Global In-Situ Hybridization Sales 2014-2025
    • 2.2 In-Situ Hybridization Growth Rate by Regions
      • 2.2.1 Global In-Situ Hybridization Sales by Regions
      • 2.2.2 Global In-Situ Hybridization Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 In-Situ Hybridization Sales by Manufacturers
      • 3.1.1 In-Situ Hybridization Sales by Manufacturers
      • 3.1.2 In-Situ Hybridization Sales Market Share by Manufacturers
      • 3.1.3 Global In-Situ Hybridization Market Concentration Ratio (CR5 and HHI)
    • 3.2 In-Situ Hybridization Revenue by Manufacturers
      • 3.2.1 In-Situ Hybridization Revenue by Manufacturers (2014-2019)
      • 3.2.2 In-Situ Hybridization Revenue Share by Manufacturers (2014-2019)
    • 3.3 In-Situ Hybridization Price by Manufacturers
    • 3.4 In-Situ Hybridization Manufacturing Base Distribution, Product Types
      • 3.4.1 In-Situ Hybridization Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers In-Situ Hybridization Product Type
      • 3.4.3 Date of International Manufacturers Enter into In-Situ Hybridization Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global In-Situ Hybridization Sales by Product
    • 4.2 Global In-Situ Hybridization Revenue by Product
    • 4.3 In-Situ Hybridization Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global In-Situ Hybridization Breakdown Data by End User

    6 North America

    • 6.1 North America In-Situ Hybridization by Countries
      • 6.1.1 North America In-Situ Hybridization Sales by Countries
      • 6.1.2 North America In-Situ Hybridization Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America In-Situ Hybridization by Product
    • 6.3 North America In-Situ Hybridization by End User

    7 Europe

    • 7.1 Europe In-Situ Hybridization by Countries
      • 7.1.1 Europe In-Situ Hybridization Sales by Countries
      • 7.1.2 Europe In-Situ Hybridization Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe In-Situ Hybridization by Product
    • 7.3 Europe In-Situ Hybridization by End User

    8 Asia Pacific

    • 8.1 Asia Pacific In-Situ Hybridization by Countries
      • 8.1.1 Asia Pacific In-Situ Hybridization Sales by Countries
      • 8.1.2 Asia Pacific In-Situ Hybridization Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific In-Situ Hybridization by Product
    • 8.3 Asia Pacific In-Situ Hybridization by End User

    9 Central & South America

    • 9.1 Central & South America In-Situ Hybridization by Countries
      • 9.1.1 Central & South America In-Situ Hybridization Sales by Countries
      • 9.1.2 Central & South America In-Situ Hybridization Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America In-Situ Hybridization by Product
    • 9.3 Central & South America In-Situ Hybridization by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa In-Situ Hybridization by Countries
      • 10.1.1 Middle East and Africa In-Situ Hybridization Sales by Countries
      • 10.1.2 Middle East and Africa In-Situ Hybridization Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa In-Situ Hybridization by Product
    • 10.3 Middle East and Africa In-Situ Hybridization by End User

    11 Company Profiles

    • 11.1 Abbott Laboratories
      • 11.1.1 Abbott Laboratories Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abbott Laboratories In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abbott Laboratories In-Situ Hybridization Products Offered
      • 11.1.5 Abbott Laboratories Recent Development
    • 11.2 F. Hoffmann-La Roche
      • 11.2.1 F. Hoffmann-La Roche Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 F. Hoffmann-La Roche In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 F. Hoffmann-La Roche In-Situ Hybridization Products Offered
      • 11.2.5 F. Hoffmann-La Roche Recent Development
    • 11.3 Leica Biosystems Nussloch
      • 11.3.1 Leica Biosystems Nussloch Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Leica Biosystems Nussloch In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Leica Biosystems Nussloch In-Situ Hybridization Products Offered
      • 11.3.5 Leica Biosystems Nussloch Recent Development
    • 11.4 Agilent Technologies
      • 11.4.1 Agilent Technologies Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Agilent Technologies In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Agilent Technologies In-Situ Hybridization Products Offered
      • 11.4.5 Agilent Technologies Recent Development
    • 11.5 Thermo Fisher Scientific
      • 11.5.1 Thermo Fisher Scientific Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Thermo Fisher Scientific In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Thermo Fisher Scientific In-Situ Hybridization Products Offered
      • 11.5.5 Thermo Fisher Scientific Recent Development
    • 11.6 Merck
      • 11.6.1 Merck Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Merck In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Merck In-Situ Hybridization Products Offered
      • 11.6.5 Merck Recent Development
    • 11.7 PerkinElmer
      • 11.7.1 PerkinElmer Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 PerkinElmer In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 PerkinElmer In-Situ Hybridization Products Offered
      • 11.7.5 PerkinElmer Recent Development
    • 11.8 Exiqon A/S
      • 11.8.1 Exiqon A/S Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Exiqon A/S In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Exiqon A/S In-Situ Hybridization Products Offered
      • 11.8.5 Exiqon A/S Recent Development
    • 11.9 BioGenex Laboratories
      • 11.9.1 BioGenex Laboratories Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 BioGenex Laboratories In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 BioGenex Laboratories In-Situ Hybridization Products Offered
      • 11.9.5 BioGenex Laboratories Recent Development
    • 11.10 Advanced Cell Diagnostics
      • 11.10.1 Advanced Cell Diagnostics Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Advanced Cell Diagnostics In-Situ Hybridization Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Advanced Cell Diagnostics In-Situ Hybridization Products Offered
      • 11.10.5 Advanced Cell Diagnostics Recent Development
    • 11.11 Bio SB

    12 Future Forecast

    • 12.1 In-Situ Hybridization Market Forecast by Regions
      • 12.1.1 Global In-Situ Hybridization Sales Forecast by Regions 2019-2025
      • 12.1.2 Global In-Situ Hybridization Revenue Forecast by Regions 2019-2025
    • 12.2 In-Situ Hybridization Market Forecast by Product
      • 12.2.1 Global In-Situ Hybridization Sales Forecast by Product 2019-2025
      • 12.2.2 Global In-Situ Hybridization Revenue Forecast by Product 2019-2025
    • 12.3 In-Situ Hybridization Market Forecast by End User
    • 12.4 North America In-Situ Hybridization Forecast
    • 12.5 Europe In-Situ Hybridization Forecast
    • 12.6 Asia Pacific In-Situ Hybridization Forecast
    • 12.7 Central & South America In-Situ Hybridization Forecast
    • 12.8 Middle East and Africa In-Situ Hybridization Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 In-Situ Hybridization Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      In Situ Hybridization (ISH)
      In Situ Hybridization (ISH) is a technique that allows for precise localization of a specific segment of nucleic acid within a histologic section.
      The underlying basis of ISH is that nucleic acids, if preserved adequately within a histologic specimen, can be detected through the application of a complementary strand of nucleic acid to which a reporter molecule is attached.
      Visualization of the reporter molecule allows to localize DNA or RNA sequences in a heterogeneous cell populations including tissue samples and environmental samples. Riboprobes also allow to localize and assess degree of gene expression. The technique is particularly useful in neuroscience.
      The global In-Situ Hybridization market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the In-Situ Hybridization market based on company, product type, end user and key regions.

      This report studies the global market size of In-Situ Hybridization in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of In-Situ Hybridization in these regions.
      This research report categorizes the global In-Situ Hybridization market by top players/brands, region, type and end user. This report also studies the global In-Situ Hybridization market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abbott Laboratories
      F. Hoffmann-La Roche
      Leica Biosystems Nussloch
      Agilent Technologies
      Thermo Fisher Scientific
      Merck
      PerkinElmer
      Exiqon A/S
      BioGenex Laboratories
      Advanced Cell Diagnostics
      Bio SB

      Market size by Product
      Radioactive isotopes
      Non-radioactive labels
      Market size by End User
      Cancer Diagnosis
      Immunology
      Neuroscience
      Cytology
      Infectious Diseases

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global In-Situ Hybridization market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of In-Situ Hybridization market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global In-Situ Hybridization companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of In-Situ Hybridization submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of In-Situ Hybridization are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of In-Situ Hybridization market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now